RCS - Immupharma PLC - Attending JPMorgan Conference & Biotech Showcase

ImmuPharmaAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260106:nRSF7128Na&default-theme=true

RNS Number : 7128N  Immupharma PLC  06 January 2026

RNS REACH |6 JANUARY 2026

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

IMMUPHARMA AT JP MORGAN CONFERENCE & BIOTECH SHOWCASE™

12-14 January 2026 | San Francisco

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr
Sebastien Goudreau, CSO, will be attending both the JP Morgan Conference and
the Biotech Showcase from 12-14 January 2026, in San Francisco, USA.

 

The JP Morgan conference and Biotech Showcase are annual premier partnering
events, designed to provide biotechnology companies with the opportunity to
present to and connect with global Biopharma companies and investors.

 

End

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

 

 

Notes to Editors

About ImmuPharma PLC

 

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

About JP Morgan Healthcare Conference

 

The J.P. Morgan Healthcare Conference 2026 is the industry's premier
investment symposium. It draws over 8,000 attendees including pharma/biotech
executives, investors, startups, analysts, and policymakers for strategic
discussions and dealmaking.

 

About Biotech Showcase

 

Biotech Showcase in San Francisco is an investor‑focused partnering
conference held each January alongside JP Morgan Healthcare Conference week.
It is designed mainly for private and micro‑ to mid‑cap biotech companies
to meet global investors and pharma executives.

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAAKPBDOBKDFDK



            Copyright 2019 Regulatory News Service, all rights reserved